

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**

**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT  
SIGNING EQUITY INVESTMENT AND STRATEGIC COOPERATION AGREEMENT  
WITH LANOVA MEDICINES**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group signed an equity investment and strategic cooperation agreement with LaNova Medicines Limited (“**LaNova Medicines**”), pursuant to which, the Group injected its capital to the equity interests of LaNova Medicines with its self-raised funds, and established a strategic cooperation in the Mainland China region for LM-108 and various potential innovative bispecific antibody or antibody-drug conjugate (ADC) in the future.

**Equity Investment**

On 18 October 2024, LaNova Medicines announced that it completed the Series C1 financing amounting to RMB300 million, by which the raised funds would be utilized for expediting the development of clinical pipelines and the construction of innovative platforms. Pursuant to the capital increase and subscription agreement, the Group (as the leading investor in this series of financing) paid RMB142 million to LaNova Medicines, thus acquiring 4.91% equity interests in LaNova Medicines after the transaction.

**Strategic Cooperation**

The Group entered into a strategic cooperation agreement with LaNova Medicines in the Mainland China region for LM-108. In addition, the Group has the option to enter into further cooperations with LaNova Medicines for various innovative bispecific antibody and ADC drugs in its pipelines, with specific terms to be agreed otherwise.

LM-108 is a monoclonal antibody targeting CCR8 independently developed by LaNova Medicines based on its exclusive multiple transmembrane protein antibody discovery platform. CCR8 specifically expresses in the regulatory T-cell (Treg) in the tumor microenvironment, and only overexpresses in tumor-infiltrating Treg, and basically does not express in peripheral blood<sup>1</sup>. Currently, CCR8 is observed to specifically express in Treg of breast cancers, lung cancers, colorectal cancers, as well as head and neck cancers. LM-108 can specifically remove tumor-infiltrating Treg without prejudice to the peripheral Treg, thus enhancing its immune killing effect on tumor cells.

LM-108 is currently at the Phase II clinical stage and ranked the first in China and ranked among the top three globally among the projects with the same target in terms of development progress. As shown by the data from early explorations and clinical studies, LM-108 demonstrates good safety and efficacy in treatments for various solid tumors, and is expected to provide patients suffering from advanced tumors with a better option for treatment.

### **Benefits of the Cooperation**

Oncology is one of the Group's key therapeutic areas for innovative development. After years of in-depth development, multiple blockbuster products have been approved for marketing and multiple innovative drug projects are at the clinical development stage. LaNova Medicines is a company focusing on the research and development (R&D) of innovative drugs in the field of oncology, with a monoclonal antibody screening platform, a bispecific antibody technology platform and an ADC drug development technology platform. It has also established a number of differentiated innovative drug pipelines under R&D. The Group has accumulated abundant advantages and resources in terms of clinical development and commercialization in the biopharmaceutical industry. Through the equity investment and strategic cooperation, the Group's pipeline layout in the field of oncology will be further enriched and optimized. The Group will also provide comprehensive support to LaNova Medicines for the development and commercialization of its innovative drug pipelines, thus expediting the marketing process of their products for the benefits of more cancer patients.

### **About LaNova Medicines**

LaNova Medicines is a China-based, globally-focused biopharmaceutical company founded in 2019 by experienced experts in the biopharmaceutical industry. With the mission of "Care for Life, Dedicate to Innovation", LaNova Medicines focuses on the unmet therapeutic needs in the fields of tumor immunology and tumor microenvironment, and on the R&D of biological innovative drugs with the potential of becoming "first-in-class" and "best-in-class". LaNova Medicines has comprehensive R&D capabilities across the entire industry chain, particularly focusing on the R&D of large molecule anti-tumor drugs targeting GPCR and multiple transmembrane proteins. It also possesses development platforms for ADC drugs and bispecific antibodies to implement differentiated routes for drug development. Currently, LaNova Medicines has already established a number of differentiated innovative drug pipelines with independent intellectual property rights and global competitiveness, and successfully promoted a number of innovative drug projects to world-leading clinical stages. Among them, LM-302 (anti-CLDN18.2 ADC) is in Phase III registrational clinical trial in China; LM-108 (anti-CCR8 monoclonal antibody) is in clinical Phase II; LM-101 (anti-SIRP  $\alpha$  monoclonal antibody), LM-305 (anti-GPRC5D ADC, with the global rights and interests licensed to AstraZeneca), LM-299 (anti-

PD-1/VEGF bispecific antibody, with the global rights and interests licensed to MSD), and LM-24C5 (anti-CEACAM5/4-1BB bispecific antibody) are all in clinical Phase I. Through continuous innovation and strategic cooperation, LaNova Medicines is committed to expediting the advancement of its product pipeline to benefit patients around the world.

*Sources:*

- [1] Campbell JR, et al. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models. *Cancer Res.* 2021 Jun 1;81(11):2983-2994.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 20 November 2024

*As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*